Biol Psychiatry

1. XIAO Y, Li M, Liao J, Yan J, et al
   CINP: a causality-informed framework for generalizable and replicable neuroimaging prediction of antipsychotic response in schizophrenia.
   Biol Psychiatry. 2026 Mar 13:S0006-3223(26)01103.
   

   >> Share

   
   
2. XU B, Dijkzeul A, Zhang Y, Schuurmans IK, et al
   Genetic susceptibility to schizophrenia and the onset of brain developmental change in adolescence.
   Biol Psychiatry. 2026 Mar 13:S0006-3223(26)01104.
   

   >> Share

   
   
3. CHOPRA S
   Variability Is the Norm in Magnetic Resonance Imaging of Psychosis.
   Biol Psychiatry. 2026;99:515-516.
   

   >> Share

   
   
4. ZHANG D, Wang J
   Successful Nonpharmacological Treatment Strategy for Cognitive Impairment in Individuals With Schizophrenia.
   Biol Psychiatry. 2026;99:511-512.
   

   >> Share

   
   

   
   Mol Psychiatry

5. SEUFFERT S, Mulfarth RR, Teutenberg L, Thomas-Odenthal F, et al
   Linking speech patterns to brain structure in affective and psychotic disorders: an integrative natural language processing approach.
   Mol Psychiatry. 2026;31:2057-2068.
   

   >> Share

   
   
6. LI Q, Liu J, Pearlson GD, Chen J, et al
   Spatiotemporal complexity in the psychotic brain.
   Mol Psychiatry. 2026;31:2014-2028.
   

   >> Share

   
   

   
   PLoS One

7. FIVEL L, Lavandier M, Grimault N, Perrin F, et al
   Is it inside my head? Characterization of sound externalization in schizophrenia.
   PLoS One. 2026;21:e0345074.
   

   >> Share

   
   
8. 
   Expression of Concern: Schizophrenia as a Network Disease: Disruption of Emergent Brain Function in Patients with Auditory Hallucinations.
   PLoS One. 2026;21:e0345144.
   

   >> Share

   
   
9. MASUMO Y, Kanahara N, Otsuka Y, Sudo Y, et al
   Neural substrates of treatment-resistant schizophrenia and the response to clozapine: A structural MRI study in a clinical setting.
   PLoS One. 2026;21:e0345078.
   

   >> Share

   
   
10. HOSSAIN MM, Tawhid MNA
    Exploring brain lobe-specific insights in an explainable framework for EEG-based schizophrenia detection.
    PLoS One. 2026;21:e0334389.
    

    >> Share

    
    

    
    Psychiatry Res

11. MOU L, Gong B, Tan Q, Wang H, et al
    Classification of functional near-infrared spectroscopy (fNIRS) signals in schizophrenia and bipolar disorder using deep learning methods.
    Psychiatry Res. 2026;360:117084.
    

    >> Share

    
    
12. CORRELL CU, Yildirim M, Zhang Z, Palma AM, et al
    Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of Phase 3 clinical trials in adults and adolescents.
    Psychiatry Res. 2026;360:117091.
    

    >> Share

    
    
13. LI YW, Yeh TC, Chien WC, Chung CH, et al
    Role of depression and anxiety in the treatment modalities and age-stratified dementia risk in patients with schizophrenia, a real-world nationwide cohort study.
    Psychiatry Res. 2026;360:117061.
    

    >> Share

    
    
14. GOH KK, Chen PY, Chang HM, Kanahara N, et al
    Longitudinal associations among childhood trauma, oxytocin, and metabolic risk in schizophrenia.
    Psychiatry Res. 2026;360:117088.
    

    >> Share

    
    
15. SEDEF MM, Oruc EB, Bulut SD, Hatil SI, et al
    Zonulin as an endophenotype for schizophrenia: A study in patients and unaffected siblings.
    Psychiatry Res. 2026;360:117102.
    

    >> Share

    
    

    
    Schizophr Res

16. ZHAO C, Lin B, Naderi E, Moazzen S, et al
    Genetic susceptibility of cardiometabolic outcomes in schizophrenia spectrum disorders.
    Schizophr Res. 2026;292:103-115.
    

    >> Share

    
    
17. NAGENDRA A, Mesholam-Gately R, Shafrin J, Keshavan MS, et al
    Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperative.
    Schizophr Res. 2026;292:96-102.
    

    >> Share

    
    
18. TANG JY, Wong GH, Zhou H, Zhou J, et al
    Ten-year risk prediction models for atherosclerotic cardiovascular disease in Chinese patients with schizophrenia-spectrum disorders: A population-based cohort study.
    Schizophr Res. 2026;292:88-95.
    

    >> Share

    
    
19. CANO JF, Galindo-Pita S, Mendez D, Vallejo-Silva A, et al
    Association between Toxoplasma gondii IgG seropositivity and schizophrenia: A case-control study in Colombia.
    Schizophr Res. 2026;292:79-87.
    

    >> Share

    
    
20. SABE M, Grof P, Sackett NB, Tai S, et al
    Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.
    Schizophr Res. 2026;292:69-78.
    

    >> Share

    
    
21. TARGUM SD, Watson C, Claxton A, Nicolas P, et al
    Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.
    Schizophr Res. 2026;292:53-59.
    

    >> Share

    
    
22. SHEPHERD R, Stacey D, Janetzki J, Clark SR, et al
    Disentangling the relationship between psychiatric disorders, cardiometabolic abnormalities, and antipsychotics: A systematic review of genomic studies.
    Schizophr Res. 2026;291:119-134.
    

    >> Share

    
    
23. DAZZAN P, Shivakumar G, Szymaniak K, Bell E, et al
    Restoring scientific resilience through European collaboration.
    Schizophr Res. 2026;290:30-33.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share